{
    "nctId": "NCT02418481",
    "briefTitle": "Safety and Efficiency of \u03b3\u03b4 T Cell Against Breast Cancer(Her-, er-, and pr-)",
    "officialTitle": "\u03b3\u03b4 T Cell Immunotherapy for Treatment of Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 40,
    "primaryOutcomeMeasure": "Reduced size of the tumors",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Age:18-75\n2. Karnofsky performance status \\>50\n3. Diagnosis with breast tumors based on histology or the current accepted radiological measures.\n4. Classification tumor,nodes,metastasis-classification(TNM) stage: \u2161,\u2162,\u2163\n5. Will receive cryosurgery, gd Tcells/ DC-CIK.\n6. Life expectancy: Greater than 3 months\n7. Ability to understand the study protocol and a willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n1. Patients with other kinds of cancer\n2. History of coagulation disorders or anemia\n3. Patients with heart disease and diabetes",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}